China’s lipid-lowering field has reached a historic moment.
On January 28, Novartis announced that the National Medical Products Administration had approved an expanded indication for its long-acting lipid-lowering therapy inclisiran. Used with diet and without the need for any additional drug, it can now lower lipid levels in patients with hyperlipidemia with just two injections per year.
Over the past decades, despite rapid progress in new therapies and regimens, daily statin treatment has remained the indispensable first-line recommendation and the cornerstone of prevention and treatment for atherosclerotic cardiovascular disease.
Prof. Zhenyue Chen, director physician in cardiology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, told MedJ that the new indication means inclisiran can now be used alone in China’s primary-prevention population with atherosclerotic cardiovascular disease risk, rather than only on top of statins or in patients who cannot tolerate statins. “That is a very big change,” Prof. Chen said.
The United States approved inclisiran’s monotherapy indication first, in August last year. Shortly before the China approval, inclisiran had also entered the new national reimbursement list in China, with its price cut by 72%.
Breaking away from statins?
Statistics show that China has 330 million people with cardiovascular disease and about 4.58 million deaths each year, accounting for more than 40% of all deaths. Atherosclerotic cardiovascular disease, including stroke, coronary heart disease, and myocardial infarction, is a leading cause.
A major risk factor for atherosclerotic cardiovascular disease is hyperlipidemia dominated by elevated LDL-C. As one of the most common abnormal screening findings, high LDL-C greatly increases the risk of heart attack, stroke, and sudden death.
Inclisiran is a small interfering RNA drug and the first clinically accessible long-acting nucleic-acid therapy in atherosclerotic cardiovascular disease prevention and treatment. It achieves precise gene silencing in the body, blocking the translation of disease-causing genes into proteins.
In hyperlipidemia, it works by inhibiting the synthesis and secretion of the relevant protein, promoting LDL-C clearance. Because small interfering RNA drugs have a long half-life, the effect lasts about six months, enabling lipid control with one injection every half year.
The U.S. Food and Drug Administration approved inclisiran in December 2021. China approved it in August 2023, but only for patients whose LDL-C remained uncontrolled despite maximally tolerated statins, or for patients with statin intolerance or a contraindication to statins.
Now that it has formally broken away from statins in China, Prof. Chen told MedJ that the move may be based on the global phase 3 V-MONO trial.
A study published in the Journal of the American College of Cardiology in May 2025 showed that over six months, inclisiran monotherapy produced larger LDL-C reductions than placebo and cholesterol-absorption-inhibitor therapy, and the same pattern was seen in participants who had previously received statins.
At present, however, guidelines around the world still regard statins as irreplaceable first-line drugs, so whether inclisiran will fully replace them has become a major clinical question.
Will statins leave the stage?
For a long time, cardiovascular end-point events have been the gold standard for judging efficacy in cardiovascular prevention: once a new therapy lowers a risk marker, the real question is whether it improves final health outcomes.
That is precisely why statins have long been viewed as the foundation of atherosclerotic cardiovascular disease prevention and treatment.
Prof. Chen told MedJ that over the past several decades, statin trials have covered virtually all primary- and secondary-prevention populations in cardiovascular disease, including acute and chronic coronary syndromes, stroke, diabetes, and hypertension. Real-world experience and follow-up are both extensive, making the efficacy and safety evidence extremely strong.
By contrast, no cardiovascular outcome results for inclisiran have yet been released. In that setting, its approval for monotherapy based largely on LDL-C reduction alone reflects growing evidence that adherence itself has become an independent risk factor in cardiovascular disease, Prof. Chen said.
Statins must be taken every day. “In practice, adherence is poor. Many patients take them on and off or stop them on their own when they have no symptoms, and LDL-C target attainment is not ideal,” he said.
“Irregular treatment also causes cholesterol fluctuations, which can drive atherosclerosis and increase the likelihood of cardiovascular events.”
“With a nucleic-acid drug given by injection, patients cannot change their mind for at least half a year. That solves the adherence problem clinicians find most frustrating and reduces management costs. Better adherence means better LDL-C reduction and better target attainment,” Prof. Chen said.
Even so, he emphasized that statins are far from being replaced, at least in the short term.
“To replace statins completely, we would need head-to-head evidence showing that inclisiran alone is not inferior or even superior to statins alone. That kind of study is unlikely to be done now, and its practical value would be limited.”
Mechanistically, statins inhibit cholesterol synthesis at the source, whereas inclisiran and other PCSK9-targeted agents promote cholesterol clearance. “For high-risk patients who need intensive lipid lowering, combination therapy can produce a one plus one greater than two effect and remains the clinical mainstream,” Prof. Chen explained.
Cost is another major consideration. After reimbursement listing earlier this year, the annual treatment cost of inclisiran in China fell from nearly RMB 20,000 to about RMB 5,600, but it is still several to dozens of times more expensive than statins.
In addition, the reimbursed indication for inclisiran is still second-line treatment after statins, and the newly approved monotherapy indication has not yet been included.
Lifestyle change remains essential
Although guidelines may not change quickly, Prof. Chen told MedJ that in real-world practice inclisiran’s prescribing status in primary prevention of atherosclerotic cardiovascular disease has already become almost equivalent to that of statins.
In fact, some physicians had previously used it off label in certain situations. “We occasionally see patients who repeatedly say they do not want daily medication. If the only option is a daily statin, they would rather go untreated.”
“In such cases, after fully assessing cardiovascular risk and communicating with the patient, doctors may still design a patient-centered regimen. The record is usually written clearly to show that the patient strongly refused oral medication and requested another option, so the decision reflects patient-centered care rather than a disregard for indications,” Prof. Chen said.
With the new monotherapy indication, the question of whether such prescribing is reasonable should now be largely resolved.
Based on the strong cholesterol hypothesis and the fact that other PCSK9-targeted drugs have already shown cardiovascular benefit, the field generally believes that if LDL-C reduction is similar, inclisiran is likely to deliver cardiovascular benefit as well, Prof. Chen said.
“At this stage, whether to choose a statin or inclisiran will depend more on the patient’s preferences, including treatment habits, willingness, and economic status.”
Ultimately, “whether the drug is a statin, a cholesterol-absorption inhibitor, a PCSK9 monoclonal antibody, or a nucleic-acid therapy, we no longer lack interventions for primary prevention of cardiovascular disease. The key is how to improve long-term adherence to medical advice so that patient benefit can be maximized,” Prof. Chen said.
He also stressed that roughly one-third of cholesterol is dietary. “I often tell patients that whether they use oral drugs or injections, lifestyle improvement is the most fundamental, safe, effective, and economical treatment. It helps patients reach cholesterol targets, delays or even reverses atherosclerotic lesions, and reduces heart attacks and strokes.”